Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Launched by BAYER · Jun 29, 2017
Trial Information
Current as of July 07, 2025
No longer available
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
- • Previous treatment with a kinase inhibitor with known activity on TRK inhibition
- • Unable to participate in an ongoing selitrectinib clinical trial
- • Medically suitable for treatment with selitrectinib
- Exclusion Criteria:
- • Currently enrolled in an ongoing clinical study with a TRK inhibitor
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials